I
Iterion Therapeutics
Iterion Therapeutics is a venture-backed, clinical stage biotechnology company
About Iterion Therapeutics
Iterion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The company's lead product, Tegavivint, is a potent and selective inhibitor of transducin beta-like protein 1 (TBL1), a key component of the Wnt beta-catenin signaling pathway. Dysregulation of this pathway is associated with increased nuclear activity that activates genes linked to cancer and fibrosis. Iterion Therapeutics is currently enrolling patients in a Phase 1 clinical study of Tegavivint for the treatment of desmoid tumors, a rare and aggressive type of tumor. The company operates in the biopharmaceutical market, targeting oncologists and healthcare providers who treat cancer and fibrotic diseases. Iterion's business model involves the development and commercialization of its proprietary therapies, generating revenue through product sales, partnerships, and licensing agreements. The company aims to bring innovative treatments to patients with high unmet medical needs.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Iterion Therapeutics is 590 monthly website visits, down 37.2% over the last three months. Iterion Therapeutics's team grew 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Iterion Therapeutics in the Houston ecosystem
The Iterion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sante Ventures
angelMD
Lumira Ventures- VBViva BioInnovator
Venture Investors Health Fund- GVGPG Ventures
Other known investors3 additional known investors
Huntsman Cancer Institute
University of Utah- GCGOOSE Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iterion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iterion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










